Pathology and molecular biology of lung cancer;Pathologie und molekularbiologie bosartiger pulmonaler tumoren

Pathologe

Volumn 21, Issue 6, 2000, Pages 404-423

  Wiethege, T ^a   Junker, K ^a   Johnen, G ^a   Krismann, M ^a   Muller, K M ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Gene therapy; Lung; Lung cancer; Metastasis; Molecular pathology; Oncogenes; Tumor suppressor genes

Indexed keywords

CLINICAL EXAMINATION; CYTOMETRY; ELECTRON MICROSCOPY; GENE THERAPY; HISTOCHEMISTRY; HISTOPATHOLOGY; HUMAN; LUNG CANCER; METASTASIS; MOLECULAR BIOLOGY; ONCOGENE; PROGNOSIS; REVIEW; TUMOR CELL; TUMOR DIAGNOSIS; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; BIOPSY; CHROMOSOME ABERRATION; GENETICS; LUNG TUMOR; METHODOLOGY; PATHOLOGY;

BIOPSY; CHROMOSOME ABERRATIONS; HUMANS; LUNG NEOPLASMS; MOLECULAR BIOLOGY; PROGNOSIS;

EID: 0033626017     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002920000409     Document Type: Review

References (124)

1. Maintenance of genomic integrity by p53: Complementary roles for activated and non-activated p53
2. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas
3. Screening for putative radon-specific p53 mutation hotspot in German uranium miners
4. Mechanisms of p53-mediated apoptosis
5. p53 Protein accumulates frequently in early bronchial neoplasia
6. Surfactant protein gene expression in metastatic and micrometastatic pulmonary adenocarcinomas and other non small cell lung carcinomas: Detection by reverse transcriptase-polymerase chain reaction
7. Myc family amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regiemns
8. Her2/neu expression and effects of herceptin alone and in combination with cytotoxic agents in lung cancer
9. New aspects in the staging of lung cancer: Prospective validation of the International Union Against Cancer TNM classification
10. The biology of the lung cancer
11. P53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer: A preliminary report of LCSG 871
12. Biology of lung cancer
13. Mutations in the p53 gene are frequent in primary, resected non small lung cancer
14. Modulation of activity of the promotor of the human MDR1 gene by ras and p53
15. Clonal evolution of lung tumors
16. Nuclear p53 overexpression is an independent prognostic parameter in node-negative nonsmall cell lung carcinoma
17. DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis
18. Alterations of CDKN2 (p16) in non-small cell lung cancer
19. HER-2/neu protein: A target for antigen-specific immuntherapy of human cancer
20. Molekularbiologie maligner tumorerkrankungen
21. Altered retinoblastoma protein expression in nonsmall cell lung cancer: Its synergistic effects with altered ras and p53 protein status on prognosis
22. Diagnostics and staging as a basis for planning therapy in lung cancer
23. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer
24. Pathologie der pulmonalarterien bei lungentumoren
25. Molecular pathogenesis of lung cancer
26. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma
27. The molecular and cellular basis of human lung cancer
28. Characteriaztion of variant subclasses of cell line derived from small cell lung cancer having distinct biochemical, morphological and growth properties
29. The natural history of lung cancer: A review based on rates of tumor growth
30. Oncogenes and antioncogenes in lung tumorigenesis
31. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
32. Abnormalities in structure and expression of the retinoblastoma gene in SCLC
33. p53 Null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas
34. Etiology of lung cancer
35. Classification of isolated tumor cells and micrometastasis
36. MDM2 gene amplification and expression in non-small-cell lung cancer: Immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation
37. Retinoblastoma protein expression in lung cancer: An immunohistochemical analysis
38. High prevalence of bcl-2 oncoprotein expression in small cell lung cancer
39. p53 Gene mutation analysis in tumors of patients exposed to a-particles
40. Somatic point mutations in the p53 gene of human tumors and cell lines. Updated compilation
41. P53 gene alterations in human tumors: Perspectives for cancer control
42. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer
43. Spektrum neuroendokriner tumoren der lunge
44. Molecular epidemiology of human cancer: Contribution of mutation spectra studies of tumor suppressor genes
45. Increased expression of mutant forms of p53 oncogene in primary lung cancer
46. The dual role model for p53 in maintaining genomic integrity
47. Myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course
48. Myc family DNA amplification in small cell lung cancer cell lines and tumors
49. Metastasierungsmuster beim bronchialkarzinom
50. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B
51. p185(neu) Expression in lung adenocarcinomas predicts shortened survival
52. Retropharyngeal rhabdomyosarcoma mimicking pseudotumor cerebri
53. Mutation and cancer: Statistical study of retinoblastoma
54. Mutant p53 protein associated with chemosensitivity in breast cancer specimens
55. Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer
56. Risk factors for lung cancer in young adults
57. Lung cancer histologic types and age of onset
58. Molecular pathologic substaging in 244 stage I non-small cell lung cancer patients
59. Regulation of p53 in response to DNA damage
60. p53 Mutation and MDM2 amplification in human soft tissue sarcomas
61. The 1993 Walter Hubert Lecture - The role of the p53 tumour suppressor gene in tumorigenesis
62. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland
63. Lung cancer deaths in the United States from 1979 to 1992: An analysis using multiple-cause mortality data
64. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines
65. Absence of activating mutations of the rRAF1 protooncogene in human lung cancer
66. A new international staging-system for lung cancer
67. Revisions in the international system for staging lung cancer
68. Neues zur pathologie der lungentumoren
69. Probleme der morphologischen klassifikation bosartiger lungentumoren
70. Stromareaktionen in lungentumoren -Tumorvernarbung und sogenanntes narbenkarzinom
71. Wert und bedeutung pathologisch-anatomischer befunde fur die thoraxchirurgie
72. Nichtkleinzellige lungentumoren - Morphologie, tumorregression, molekularpathologie
73. Small cell carcinoma of the lung: Pathological anatomy
74. Pathologie kleinzelliger lungentumoren
75. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
76. Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas
77. Bcl-2 and p53 protein expression in non-small cell lung cancers: Correlation with survival time
78. Mutations in the p16(INK4)/MTS1/CDKN2, p15(INK4B)/MTS2, and p18 genes in primary and metastatic lung cancer
79. p53 - The first twenty years
80. Disseminierte tumorzellen: Diagnostik, prognostische relevanz, phanotypisierung und therapeutische strategien
81. Patterns of chromosomal imbalances in adenocracinoma and squamous cell carcinoma of the lung
82. Small cell lung cancer is characterized by a high incidence of deletions on chromosomes 3p, 4q, 5q, 10q, 13q, and 17p
83. Bcl-2 protein in non-small-cell lung carcinoma
84. Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas
85. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
86. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung
87. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer
88. Molecular events in lung cancer
89. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IlIa non-small-cell lung cancer
90. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer
91. Antibodies against murine double minute-2 (mdm2) in sera of patients with various gynaecological diseases
92. Reciprocal Rb inactivation and p16(INK4) expression in primary lung cancers and cell lines
93. Deletion of a splice donor site ablates expression of the following exons and produces an unphosphorylated RB protein unable to bind SV40 T antigen
94. RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma
95. Growth factors and recpetors in non-small cell lung cancer
96. Addition of Herceptin(TM) (humanized anti Her2 antibody) to first line chemotherapy for Her2 overexpressing metastic breast cancer markedly increases anticancer activity: A randomized multinational controlled phase III trials
97. Studies of the HER-2/neu Proto-oncogene in human breast and ovarian cancer
98. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung
99. Low p53 protein expression in salivary gland tumours compared with lung carcimomas
100. p53 Antibodies in the sera of patients with various types of cancer: A review
101. The FHIT gene 3p14.2 is abnormal in lung cancer
102. K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas
103. Altered cJUN expression: An early event in human lung carcinogenesis
104. P53 Mutation hotspot in radon-associated lung cancer
105. p53-Dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents
106. Gender differences in p53 mutational status in small cell lung cancer
107. Involvement of the bcl-2 gene in human follicular lymphoma
108. Prognostic value of oncoproteins for the survival of patients with non-small cell lung carcinomas
109. Prognostic significance of the expression of c-fos, c-jun and erbB-1 oncogene products in human squamous cell lung carcinomas
110. C-K-ras and c-N-ras are important and stage-independent prognostic indicators in adenocarcinomas of the lung
111. Expression of the BCL-2 protein in normal and dysplastic bronchial epithelium and in lung carcinomas
112. Clinical implications of p53 mutations
113. Specific chromosome defects associated with human small-cell lung cancer;deletion 3p(14-23)
114. Detection of MDM2 - Proto-oncogene in paraffin embedded human bronchial epithelium
115. Immunhistochemische untersuchungen zur akkumulation des tumor-suppressor-gens p53 in bronchialkarzinomen
116. PS3 and chemosensitivity
117. Codeletion of p15 and p16 genes in primary non-small cell lung cancer
118. Altered retinoblastoma (RB) and p53 protein status as a synergistic prognostic factor in non-small cell lung carcinoma
119. Analysis of radon-associated squamous cell carcinomas of the lung for a p53 gene hot spot mutation
120. Altered expression of the retinoblastoma (RB) gene in small cell carcinoma of the lung
121. Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung
122. Activation of Ki-ras protooncogene in spontaneously occuring and chemically induced lung tumors of strain A mouse